The sale marks the end of a decade-long investment for KKR, which first acquired Goodpack in 2014 through a privatisation of the then Singapore-listed group. The Lam family is understood to have retained a minority stake following that transaction. KKR had explored options to exit Goodpack since 2020 and formally put the business up for sale in October 2024. Infrastructure investor I Squared Capital was previously reported as a frontrunner, with Brookfield Asset Management and Apollo Global Management also said to have shown interest. Founded in 1980, Goodpack operates a global leasing model for reusable pallet-sized intermediate bulk containers used to transport high-value payloads by road, rail, and sea. The business serves multinational clients across industrial and logistics supply chains. A source said the buyback reflects the family's belief that Goodpack is entering a new phase of growth as global customers redesign supply chains to improve resilience, efficiency, and sustainability....
The Milan-based firm said the fund targets mid-market borrowers whose products and services are driven by environmental sustainability rather than regulatory incentives. Around '300m has already been deployed across 13 companies operating in areas such as energy infrastructure, water, and food ingredients. Ran Landmann, partner and chief investment officer of Ambienta's credit arm, said the strategy around ESG remains a focus for the company. 'Our goal remains unchanged, deliver credit solutions that are both financially robust and environmentally impactful. By focusing on rigorous credit selection and supporting companies advancing sustainability, we can create long-term value for our investors and the communities they serve,' he said. Founded in 2007, Ambienta manages more than '4bn in assets. The fund launch comes as private credit managers increasingly carve out specialist strategies to differentiate themselves in a crowded European lending market. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today....
When sitting firmly in the post-trade environment, it is not immediately clear why firms such as clearinghouses and custodians should be concerned with managing sanctions risk (see sidebar 'What are sanctions''). Surely that would be handled by banks, brokers, and other parties earlier in the trade life cycle. In fact, that's not the case. Recent regulatory enforcement actions make it clear that securities services firms with exposure to sanctioned countries carry a high level of responsibility. And the cost of noncompliance is high: In the European Union, regulators have levied fines of '480 million since 2017 (compared with approximately '57 million in the United States), including about '90 million in 2024 alone.1'EU sanctions enforcement has tightened but varies between countries - experts,' Baltic Times, June 11, 2025. As of March 2025, there were 82,000 persons (individuals and entities) designated for sanctions globally, a nearly fivefold increase from 2017. In the United Kingdom and European Union, the number of designations doubled between 2020 and 2023. Given those numbers, how well equipped are the world's leading securities services firms to meet their obligations'...
Researchers in Class of 1942 Professor of Chemistry Matthew D. Shoulders' lab have uncovered a sinister hidden mechanism that can allow cancer cells to survive (and, in some cases, thrive) even when hit with powerful drugs. The secret lies in a cellular 'safety net' that gives cancer the freedom to develop aggressive mutations. This fascinating intersection between molecular biology and evolutionary dynamics, published Jan. 22 on the cover of Molecular Cell, focuses on the most famous anti-cancer gene in the human body, TP53 (tumor protein 53, known as p53), and suggests that cancer cells don't just mutate by accident ' they create a specialized environment that makes dangerous mutations possible. Tasked with the job of stopping damaged cells from dividing, the p53 protein has been known for decades as the 'guardian of the genome' and is the most mutated gene in cancer. Some of the most perilous of these mutations are known as 'dominant-negative' variants. Not only do they stop working, but they actually prevent any healthy p53 in the cell from doing its job, essentially disarming the body's primary defense system....
